The risk of reactivation or de novo hepatitis B in liver transplant recipients from anti-HBc-positive donors with chronic hepatitis B and HBsAg-negative recipients was 5.8 % and 3.5 %, respectively (Fig. 3). This evidence concerns the gene KRT88P and hepatitis B virus infection.